INTRODUCTION {#S1}
============

Interleukin-27 (IL-27), a member of the IL-6/IL-12 cytokine superfamily, is a heterodimer composed of two noncovalently associated subunits: Epstein-Barr virus-induced gene 3 (EBI3) and IL-27p28 ([@R55]). The IL-27 receptor is also a heterodimer composed of the IL-27 receptor subunit alpha (IL-27Rα) and a signal transduction subunit, glycoprotein 130 (gp130) ([@R56]). IL-27 is secreted primarily by activated dendritic cells (DCs), monocytes, and macrophages, and the receptor complex is expressed on many immune cells, including T cells, B cells, DCs, macrophages, and natural killer cells ([@R81]). IL-27 signaling activates signal transducer and activator of transcription (STAT) family proteins STAT1 and STAT3, as well as the mitogen-activated protein kinase (MAPK) pathway ([@R69]; [@R43]; [@R54]; [@R51]). IL-27 has been shown to have both pro- and anti-inflammatory activities in several autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease ([@R45]).

Type 1 diabetes (T1D) is an autoimmune disease characterized by the T cell-mediated destruction of insulin-producing pancreatic β cells ([@R62]). Genome-wide association studies have identified more than 50 loci significantly linked to T1D in humans ([@R2]; [@R6]; [@R15]; [@R19]; [@R72]; [@R50]; [@R11]), including a region located on chromosome 16 that contains 24 protein coding genes, of which *IL27* (encoding the p28 subunit) has been indicated as a strong candidate ([@R2]; [@R4]). Expression quantitative trait loci (eQTL) analysis revealed that the T1D-associated risk allele of the SNP rs4788084 located within 2 kb upstream of *IL27* was linked to increased expression of *GBP4* and *STAT1* in human peripheral blood mononuclear cells (PBMCs) ([@R78]). Subsequently, an *IL27* missense variant (rs181206) was found in strong linkage disequilibrium with rs4788084, and eQTL analysis indicated that the rs181206 variant was associated with elevated *STAT1* and *IRF1* transcript levels in human CD4 T cells ([@R35]). Interestingly, this study also demonstrated that the same rs181206 variant increased IL-27 function ([@R35]). Collectively, these genetic studies suggest the potential of *IL27* allelic variants to directly affect the downstream signaling pathway, and they could have effects on T1D pathogenesis.

Previous mouse studies aimed at understanding the role of IL-27 in T1D showed a model-dependent outcome. A study in the non-obese diabetic (NOD) mouse revealed that IL-27 was expressed by activated DCs in diabetic mice, and blockade of IL-27 significantly delayed the onset of splenocyte-transferred T1D in lymphocyte-deficient NOD-*scid* recipients ([@R77]). In contrast, another study in which diabetes was induced by multiple injections of low-dose streptozotocin showed that IL-27 signaling conferred protection against T1D ([@R20]). To better define the role of IL-27 in T1D, we generated and characterized NOD mice deficient in IL-27p28 or IL-27Rα. Our results demonstrate that IL-27 signaling in both CD4 and CD8 T cells is critical for T1D development and this cytokine directly influences differentiation and effector functions of both CD4 and CD8 T cells in pancreatic islets. In addition, we show here that IL-27 signaling in T cells is also required for lacrimal and salivary gland inflammation, indicating that its effects are not limited to β-cell autoimmunity in NOD mice.

RESULTS {#S2}
=======

IL-27 Is Required for T1D Development in NOD Mice {#S3}
-------------------------------------------------

To study the role of IL-27 in T1D, we used zinc-finger nuclease (ZFN)-mediated mutagenesis to directly target *Il27* in NOD mice ([Figure S1A](#SD1){ref-type="supplementary-material"}). Bone marrow (BM)-derived macrophages from NOD but not NOD.*Il27*^*−/−*^ mice produced IL-27 upon stimulation with lipopolysaccharide (LPS), confirming the knockout phenotype ([Figure S1B](#SD1){ref-type="supplementary-material"}). Strikingly, both female and male NOD.*Il27*^−/−^ mice were completely resistant to T1D development ([Figure 1A](#F1){ref-type="fig"}). Compared with NOD mice, insulitis was significantly reduced in 10-week-old NOD.*Il27*^−/−^ mice, and it did not further progress from 10 to 30 weeks of age ([Figures 1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}; [Figure S1C](#SD1){ref-type="supplementary-material"}).

Macrophages and DCs are the main sources of IL-27, but previous studies have also reported its production by activated T cells ([@R38]; [@R12]; [@R21]). Therefore, we tested if introducing wild-type macrophages and DCs is sufficient for T1D development in NOD.*Il27*^−/−^ mice. Sublethally irradiated NOD.*Il27*^−/−^ mice were infused with NOD.*Rag1*^−/−^ BM cells to allow partial reconstitution of wild-type macrophages and DCs in the presence of host *Il27*^−/−^ T and B cells. Sublethally irradiated NOD.*Il27*^−/−^ mice reconstituted with NOD.*Rag1*^−/−^.*Il27*^−/−^ BM cells were used as the control. NOD.*Il27*^−/−^ recipients of NOD.*Rag1*^−/−^ but not NOD.*Rag1*^−/−^.*Il27*^−/−^ BM cells progressed to diabetes ([Figure 1D](#F1){ref-type="fig"}). These results indicate that IL-27 production by non-T and non-B cells, most likely macrophages and/or DCs, is sufficient to drive T1D progression. We then asked if IL-27 production by macrophages and/or DCs is required for T1D development by transferring NOD splenic T cells into NOD.*Rag1*^−/−^ or NOD.*Rag1*^−/−^.*Il27*^−/−^ recipients. NOD.*Rag1*^−/−^ but not NOD.*Rag1*^−/−^.*Il27*^−/−^ recipients of NOD T cells developed diabetes, indicating that IL-27 production by non-T and non-B cells is required to drive T1D ([Figure 1E](#F1){ref-type="fig"}).

IL-27 Is Not Essential for the Development of β-Cell Autoreactive T Cells {#S4}
-------------------------------------------------------------------------

The striking protective phenotype in NOD.*Il27*^*−/−*^ mice prompted us to question if diabetogenic T cells are present in this strain. To test this, we transferred total splenic T cells isolated from NOD and NOD.*Il27*^−/−^ mice into NOD.*Rag1*^−/−^ recipients capable of producing IL-27. T cells from old (14- to 15-week-old) NOD.*Il27*^−/−^ and young (6- to 7-week-old) NOD mice had similar diabetogenic activity, but both were significantly less capable of inducing T1D than those from old (11- to 13-week-old) NOD mice ([Figure 1F](#F1){ref-type="fig"}). Thus, NOD.*Il27*^−/−^ mice still harbor β-cell autoreactive T cells, but the frequency is likely lower than that in NOD mice of a similar age. These results also suggest that β-cell autoreactive T cells in NOD.*Il27*^−/−^ mice are not permanently tolerized but cannot be efficiently activated and expanded. We also conclude that T cell-derived IL-27 is not required for T1D development.

IL-27 Deficiency Suppresses Islet Infiltration of DCs and T Cells {#S5}
-----------------------------------------------------------------

CD11b^−^ CD103^+^ migratory DCs are critical for autoreactive CD8 T cell activation and expansion in pancreatic lymph nodes (PLNs) ([@R17]). Therefore, we evaluated if IL-27 is important for the development of DC subsets in the PLN and spleen. Our analyses did not reveal a difference in the abundance of CD11b^−^ CD103^+^ or other DC subsets in the PLNs and spleens of 10-week-old NOD and NOD.*Il27*^−/−^ mice ([Figures S2A](#SD1){ref-type="supplementary-material"}--[S2C](#SD1){ref-type="supplementary-material"}). Furthermore, expression levels of CD40, CD80, CD86, K^d^, I-A^g7^, and PD-L1 on PLN DCs were comparable between NOD and NOD.*Il27*^−/−^ mice (data not shown). Thus, IL-27 deficiency does not cause a general defect of DC development in NOD mice.

In NOD mice, myeloid antigen-presenting cells (APCs) are among the first immune cells to infiltrate the pancreatic islets and are required for amplification of the autoreactive T cell response ([@R46]; [@R18]). Therefore, we analyzed whether IL-27 is important for the infiltration and accumulation of myeloid APCs and T cells in the islets. At 4 weeks of age, NOD and NOD.*Il27*^−/−^ mice had a similar frequency of CD45^+^ cells in the islets ([Figure 2A](#F2){ref-type="fig"}). The proportion of CD45^+^ cells dramatically increased in the islets of 10-week-old NOD mice, but it was only marginally increased from 4 to 10 weeks in the NOD.*Il27*^−/−^ mice ([Figure 2A](#F2){ref-type="fig"}). Likewise, NOD and NOD.*Il27*^−/−^ mice had a similar low frequency of islet-infiltrating CD3^+^ cells at 4 weeks of age. However, by 10 weeks of age, NOD mice showed a significant accumulation of CD3^+^ cells in the islets, while NOD.*Il27*^−/−^ mice had only a slight increase of these cells ([Figure 2B](#F2){ref-type="fig"}). Coincidentally, at 4 weeks of age, there were no differences in the overall frequencies of F4/80^+^ CD11c^−^, F4/80^+^ CD11c^+^, or F4/80^−^ CD11c^+^ APCs in the islets of NOD and NOD.*Il27*^−/−^ mice ([Figure 2C](#F2){ref-type="fig"}). However, at 10 weeks of age, the frequency of F4/80^−^ CD11c^+^ DCs, which includes CD103^+^ migratory DCs, was significantly increased in the islets of NOD mice, whereas it was largely unchanged in the absence of IL-27 ([Figure 2C](#F2){ref-type="fig"}). These data indicate that the overall infiltration of T cells and DCs into the pancreatic islets is significantly decreased in the absence of IL-27 signaling. Because initial T cell infiltration promotes maturation of CD11c^+^ APCs in islets, including upregulation of CD40 ([@R46]), we further analyzed the phenotype of islet-infiltrating myeloid APCs in NOD and NOD.*Il27*^−/−^ mice. The expression of I-A^g7^, K^d^, and CD40 was comparable in myeloid APCs between NOD and NOD.*Il27*^−/−^ mice at 4 weeks of age (data not shown). In contrast, at 10 weeks of age, myeloid APCs from NOD islets had significantly increased CD40 expression compared with NOD.*Il27*^−/−^ mice despite comparable levels of I-A^g7^ ([Figure 2D](#F2){ref-type="fig"}). Reduced CD40 expression on intra-islet myeloid APCs as a result of IL-27 deficiency is consistent with the significantly decreased T cell infiltration and disease progression in NOD.*Il27*^−/−^ mice.

Activation of β-Cell Autoreactive CD8 T Cells in PLNs Is Significantly Reduced in NOD.*Il27*^−/−^ Mice {#S6}
------------------------------------------------------------------------------------------------------

Although NOD.*Il27*^−/−^ mice still harbor β-cell autoreactive T cells ([Figure 1F](#F1){ref-type="fig"}), it is possible that their activation in PLNs is reduced. To test this hypothesis, we used T cell receptor (TCR) transgenic β-cell autoreactive BDC2.5 CD4 and NY8.3 CD8 T cells ([@R76]; [@R36]). We transferred eFluor670-labeled BDC2.5 CD4 or NY8.3 CD8 T cells into NOD and NOD.*Il27*^−/−^ recipients and analyzed their activation in PLNs 5 days after transfer. Proliferation as well as the expression of CD44 and CD62L of adoptively transferred BDC2.5 CD4 T cells were comparable in NOD and NOD.*Il27*^−/−^ mice ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). However, both proliferation and the activation phenotype (CD44^high^ and CD62L^neg^) of transferred NY8.3 CD8 T cells were significantly reduced in the PLNs of the NOD.*Il27*^−/−^ strain compared with NOD mice ([Figures 3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}). Thus, IL-27 deficiency significantly suppressed the activation of β-cell autoreactive CD8 T cells and had less effect on the activation of CD4 T cells in PLNs.

To initially test whether the decreased activation of NY8.3 CD8 T cells in NOD.*Il27*^−/−^ mice is due to an impairment in the early event of antigenic stimulation, we isolated splenic CD8 T cells from NOD.*Cd45.2.NY8.3* mice and transferred them into NOD and NOD.*Il27*^−/−^ recipients. Sixteen hours later, the expression level of the early activation marker CD69 on transferred CD45.2^+^ NY8.3 CD8 T cells in the PLNs was significantly lower in NOD.*Il27*^−/−^ mice than in NOD recipients ([Figure 3E](#F3){ref-type="fig"}). Similarly, CD44 expression on transferred NY8.3 CD8 T cells was significantly reduced in the PLNs of NOD.*Il27*^*−/−*^ recipients ([Figure 3F](#F3){ref-type="fig"}). This result suggests that antigenic stimulation of β-cell autoreactive CD8 T cells in PLNs is reduced in the IL-27-deficient mice, likely because of decreased β-cell antigen availability as a result of limited DC infiltration in islets.

IL-27 Receptor Is Essential for T1D Development in NOD Mice {#S7}
-----------------------------------------------------------

To further confirm that loss of IL-27 signaling in NOD.*Il27*^−/−^ mice was responsible for diabetes protection, we used CRISPR/Cas9 to target *Il27ra* directly in NOD mice ([Figure S1A](#SD1){ref-type="supplementary-material"}), resulting in the absence of IL-27Rα protein ([Figure S1D](#SD1){ref-type="supplementary-material"}). NOD.*Il27ra*^−/−^ mice of both sexes were also completely resistant to T1D development ([Figure 4A](#F4){ref-type="fig"}). Compared with NOD mice, NOD.*Il27ra*^−/−^ mice also had significantly decreased insulitis at 10 weeks and limited progression from 10 to 30 weeks ([Figures 4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}; [Figure S1C](#SD1){ref-type="supplementary-material"}). These results confirm that IL-27 signaling is essential for T1D development in NOD mice. Both IL-27 and IL-6 use the gp130 receptor subunit and induce expression of some common genes in CD4 T cells through STAT1-, STAT3-, and MAPK-dependent pathways ([@R57]; [@R32]; [@R24]). Therefore, we asked if IL-6 also has an important role in diabetes development in NOD mice. However, T1D development in IL-6-deficient and sufficient NOD mice was indistinguishable ([Figure S3](#SD1){ref-type="supplementary-material"}).

T Cell-Intrinsic IL-27 Signaling Is Essential for T1D Development {#S8}
-----------------------------------------------------------------

Next, we used the IL-27Rα-deficient mice to determine which cell types need to respond to IL-27 for T1D development. Using the same BM chimera approach described in [Figure 1D](#F1){ref-type="fig"}, we found that NOD.*Rag1*^−/−^ BM (capable of giving rise to non-T and non-B cells that can both produce and respond to IL-27) did not induce T1D in sublethally irradiated NOD.*Il27ra*^−/−^ mice ([Figure 4D](#F4){ref-type="fig"}). In addition, NOD splenic T cells equally induced T1D in NOD.*Rag1*^−/−^ and NOD.*Rag1*^−/−^.*Il27ra*^−/−^ recipients ([Figure 4E](#F4){ref-type="fig"}). Hence, the ability to respond to IL-27 by non-T and non-B cells is neither sufficient nor required for T1D development in NOD mice.

Therefore, we asked if T cells need to directly respond to IL-27 to cause T1D. Splenic T cells isolated from NOD or NOD.*Il27ra*^−/−^ mice were transferred into NOD.*Rag1*^−/−^ recipients to compare their diabetogenic activity. T cells isolated from NOD.*Il27ra*^−/−^ mice were unable to induce T1D in the NOD.*Rag1*^−/−^ recipients, indicating that T cells need to respond to IL-27 to induce T1D ([Figure 4F](#F4){ref-type="fig"}). It is most likely that NOD.*Il27ra*^−/−^ mice also harbor β-cell autoreactive T cells, as in the NOD.*Il27*^−/−^ strain; however, their inability to respond to IL-27 precluded them from inducing diabetes in NOD.*Rag1*^−/−^ recipients. Next, we asked if both CD4 and CD8 T cells need to respond to IL-27 for T1D development. Splenic CD4 and CD8 T cells were individually isolated from NOD or *NOD.Il27ra*^−/−^ mice, mixed in a "crisscross" design, and transferred into NOD.*Rag1*^−/−^ recipients. As expected, co-transfer of CD4 plus CD8 T cells from NOD mice induced a high incidence of diabetes, but co-transfer of both cell types from NOD.*Il27ra*^−/−^ donors did not ([Figure 4G](#F4){ref-type="fig"}). Co-transferred NOD CD4 and NOD.*Il27ra*^−/−^ CD8 T cells or NOD.*Il27ra*^−/−^ CD4 and NOD CD8 T cells were able to induce T1D but the onset was delayed and the overall incidence in both recipient groups was significantly lower than those infused with NOD CD4 and CD8 T cells ([Figure 4G](#F4){ref-type="fig"}). Therefore, IL-27 signaling in both CD4 and CD8 T cells is important for T1D development.

Direct IL-27 Signaling Does Not Alter the Suppressive Function of Regulatory T Cells {#S9}
------------------------------------------------------------------------------------

The reduced diabetogenic activity of IL-27Rα-deficient CD4 T cells could be due to altered function of effector T cells and/or regulatory T cells (Tregs). We next determined whether the decreased diabetogenicity of IL-27Rα-deficient CD4 T cells was due to the enhanced suppressive function of IL-27Rα-deficient Tregs. First, we tested the *in vitro* suppressive activities of NOD and NOD.*Il27ra*^−/−^ Tregs. We co-cultured NOD or NOD.*Il27ra*^−/−^ Tregs (CD4^+^ CD25^+^) with NOD effector cells (CD4^+^ CD25^−^) and NOD.*Rag1*^−/−^ splenocytes in the presence of anti-CD3. We found the suppressive activity of NOD and NOD.*Il27ra*^−/−^ Tregs to be similar ([Figure 4H](#F4){ref-type="fig"}; [Figure S4](#SD1){ref-type="supplementary-material"}). As the *in vitro* suppression assay does not completely reflect the complexity of Treg activities, we subsequently compared their *in vivo* functionality. Splenic Tregs (CD4^+^CD25^+^GITR^+^) were independently sorted from NOD and NOD.*Il27ra*^−/−^ mice and co-transferred with splenic CD25-depleted NOD total T cells in a 1:10 ratio (Treg/effector) into NOD.*Rag1*^−/−^ recipients. A control group received only CD25-depleted T cells and developed rapid T1D onset as expected ([Figure 4I](#F4){ref-type="fig"}). The mice receiving CD25-depleted T cells plus either NOD or NOD.*Il27ra*^−/−^ Tregs developed T1D similarly but had significantly delayed T1D onset compared with the control group ([Figure 4I](#F4){ref-type="fig"}). Therefore, IL-27 signaling in Tregs does not directly alter their ability to suppress T1D.

IL-27 Directly Affects the Composition of CD4 T Cell Subsets in Pancreatic Islets {#S10}
---------------------------------------------------------------------------------

Although IL-27 signaling does not appear to be essential for the proliferation of β-cell autoreactive CD4 T cells in PLNs, as shown by the BDC2.5 transfer experiment ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}), it may affect their effector function in islets. To further analyze the cell-intrinsic effects of IL-27 signaling on the effector function of CD4 T cells, we directly compared wild-type and *Il27ra*^−/−^ CD4 T cells in the mixed BM chimeras. We reconstituted lethally irradiated (NOD × NOD.*Cd45.2*)F1 recipients with an equal number of NOD.*Cd45.2* and NOD.*Il27ra*^−/−^ (expressing CD45.1) BM cells. Pre-diabetic chimeras were analyzed 10--12 weeks after BM reconstitution. The spleens, PLNs, and islet infiltrates of the BM chimeras were analyzed to determine if IL-27 signaling directly controls the frequency of CD4 T cells. The proportions of NOD.*Cd45.2*- and NOD.*Il27ra*^−/−^-derived total CD4 T cells were comparable in the spleens and PLNs, indicating that their overall reconstitution ability did not differ significantly ([Figure 5A](#F5){ref-type="fig"} and data not shown). The frequencies of NOD.*Cd45.2-* and NOD.*Il27ra*^−/−^-derived total CD4 T cells were also similar in the islets ([Figure 5A](#F5){ref-type="fig"}).

To further determine whether IL-27 signaling can directly control the balance of effector and regulatory CD4 T cells, we analyzed transcription factor expression and cytokine production in the mixed BM chimeras. The frequency of NOD.*Il27ra*^−/−^ derived T-bet^+^ Foxp3^−^CD4 T cells was significantly reduced compared with those originating from NOD.*Cd45.2* in the spleens, PLNs, and islets of the mixed BM chimeras ([Figure 5B](#F5){ref-type="fig"}). The frequency of NOD.*Il27ra*^−/−^-derived interferon (IFN)γ-producing Foxp3^−^ CD4 T cells was also significantly reduced in the spleens, PLNs, and islets of the mixed BM chimeras ([Figure 5C](#F5){ref-type="fig"}). There was minimal detection of IL-17A and IL-4 production (data not shown). These results indicate that IL-27 signaling directly promotes the development of a pathogenic T helper 1 (Th1) T cell response in NOD mice. On the other hand, the frequency of NOD.*Il27ra*^−/−^-derived Tregs was significantly increased compared with those of the NOD.*Cd45.2* origin in the islets and spleens but not PLNs ([Figure 5D](#F5){ref-type="fig"}). Interestingly, the ratio of NOD.*Il27ra*^−/−^ to NOD.*Cd45.2*-derived Tregs was significantly larger in the islets than in the spleens ([Figure 5D](#F5){ref-type="fig"}). This observation suggests that there is a local effect of IL-27 signaling to proportionally promote Treg accumulation in the islet environment. Further supporting this possibility is the observation that the absolute number of *Il27ra*^−/−^ Tregs was higher than those of the NOD.*Cd45.2* origin in the pancreatic islets but not the spleens and PLNs of the mixed BM chimeras ([Figure S5](#SD1){ref-type="supplementary-material"}). There was not a difference in CD25 expression on NOD.*Cd45.2-* or NOD.*Il27ra*^−/−^-derived Tregs in the islets ([Figure 5D](#F5){ref-type="fig"}), indicating that the increased frequency of NOD.*Il27ra*^−/−^-derived Tregs is not due to an enhanced ability to bind IL-2. Together these results indicate that CD4 T cell-intrinsic IL-27 signaling tips the balance between Tregs and Th1 effectors and favors the latter population in the islet environment. This is likely an important factor contributing to T1D resistance in NOD.*Il27*^−/−^ and NOD.*Il27ra*^−/−^ mice.

IL-27 Directly Promotes the Accumulation and Effector Function of CD8 T Cells in Pancreatic Islets {#S11}
--------------------------------------------------------------------------------------------------

Using the same mixed BM chimera approach described above, we further defined the intrinsic effects of IL-27 signaling on CD8 T cell frequency and function. The proportions of NOD.*Cd45.2-* and NOD.*Il27ra*^−/−^-derived total CD8 T cells were comparable in the spleens and PLNs, indicating that their overall reconstitution ability did not differ significantly ([Figure 5A](#F5){ref-type="fig"} and data not shown). Interestingly, the frequency of NOD.*Il27ra*^−/−^-derived CD8 T cells was significantly decreased compared with those of the NOD.*Cd45.2* origin in the pancreatic islets ([Figure 5A](#F5){ref-type="fig"}). This result indicates that CD8 T cell-intrinsic IL-27 signaling promotes their islet accumulation. To further define the intrinsic effects of IL-27 signaling on CD8 T cell function, we analyzed their T-bet expression and IFNγ production in the mixed BM chimera mice. The frequency of T-bet^+^ cells among total NOD.*Il27ra*^−/−^derived CD8 T cells was significantly reduced compared with those of the NOD.*Cd45.2* origin in the spleens and islets but not the PLNs of the mixed BM chimeras ([Figure 5E](#F5){ref-type="fig"}). Consistently, the frequency of NOD.*Il27ra*^−/−^-derived CD8 T cells capable of producing IFNγ was significantly reduced compared with those derived from NOD.*Cd45.2* in the islets but not the spleens or PLNs of the mixed BM chimeras ([Figure 5F](#F5){ref-type="fig"}). These results suggest that direct IL-27 signaling within pancreatic islets is important for optimal pathogenic CD8 T cell differentiation.

IL-27 Signaling in T Cells Is Required for Lacrimal and Salivary Gland Inflammation {#S12}
-----------------------------------------------------------------------------------

In addition to T1D, NOD mice spontaneously develop autoimmunity of lacrimal and salivary glands and are a well-established model of Sjögren syndrome ([@R52]). To determine if disruption of IL-27 signaling has a broader effect in autoimmunity, we analyzed lacrimal and salivary glands from NOD, NOD.*Il27*^−/−^, and NOD.*Il27ra*^−/−^ mice. In NOD mice, Sjögren syndrome-like manifestations occur in a sex-specific manner, with males spontaneously developing lacrimal gland inflammation and females developing spontaneous salivary gland inflammation ([@R29], [@R28]; [@R41]; [@R47]; [@R67]; [@R71]). Both male lacrimal and female salivary gland inflammation were significantly reduced in NOD.*Il27*^−/−^ and NOD.*Il27ra*^−/−^ mice compared with age- and sex-matched wild-type NOD mice ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). This protection was not transient as 30-week-old NOD.*Il27*^−/−^ mice showed little or no lacrimal or salivary gland inflammation, with median focus scores of 0.46 foci/4 mm^2^ (range 0.18--2.46, n = 6) and 0 foci/4 mm^2^ (range 0--0.76, n = 5), respectively. Similarly, 21-weekold NOD.*Il27ra*^−/−^ mice showed significantly decreased lacrimal gland inflammation compared with age- and sex-matched NOD mice ([Figure 6C](#F6){ref-type="fig"}). Because IL-27 signaling was required for pathogenic T cells in the context of autoimmune diabetes ([Figure 4F](#F4){ref-type="fig"}), we asked if IL-27 was similarly required for pathogenic effector T cells in the context of Sjögren syndrome-like manifestations in NOD mice. We isolated CD25-depleted splenic T cells from NOD or NOD.*Il27ra*^−/−^ males and transferred them to sex-matched NOD-*scid* recipients. NOD T cells caused typical focal lymphocytic inflammation in NOD-*scid* mice, whereas recipients of NOD.*Il27ra*^−/−^ T cells were protected from the development of lacrimal gland inflammation ([Figure 6D](#F6){ref-type="fig"}). Thus, in the absence of IL-27 signaling, effector T cells failed to adequately infiltrate lacrimal glands, demonstrating that the pathogenic role of IL-27 in driving autoimmunity in NOD mice is not limited to pancreatic islets.

DISCUSSION {#S13}
==========

In this study we aimed to better define the function of IL-27 signaling in T1D autoimmune pathogenesis. Our data show that IL-27 signaling promotes the development of insulitis and progression to T1D through multiple mechanisms. We found that IL-27 production by non-T and non-B cells was both necessary and sufficient to drive T1D progression. However, the ability of non-T and non-B cells to respond to IL-27 was neither necessary nor sufficient for T1D development. Notably, T cell-intrinsic IL-27 signaling was critical for progression to T1D. Direct IL-27 signaling in both CD4 and CD8 T cells was found to be important. CD4 T cell-intrinsic IL-27 signaling affected the balance of the Treg and Th1 effector cells and favored the latter population. Direct IL-27 signaling also promoted the accumulation of CD8 T cells in the islets and enhanced the expression of the effector molecules T-bet and IFNγ. Together, our results support a model wherein macrophage/DC-derived IL-27 promotes CD8 T cell-mediated β cell destruction directly and indirectly through modulation of CD4 T cells.

Many pro-inflammatory effects of IL-27 signaling are mediated through activation of STAT1 ([@R30]). The completely protective phenotype of NOD.*Il27*^−/−^ and NOD.*Il27ra*^−/−^ mice is particularly significant considering that NOD.*Stat1*^−/−^ mice are also completely protected from insulitis and T1D ([@R37]). In contrast, NOD mice deficient in other genes immediately upstream of STAT1 signaling, including *Il6* (reported here), *Ifng*, *Ifngr2*, and *Ifnar1*, develop insulitis and T1D ([@R63], [@R64]; [@R59]). Surprisingly, NOD mice deficient in both *Ifngr1* and *Ifnar1* still developed T1D, although the overall incidence was reduced ([@R7]). Both type I and type II interferon (IFN) pathways can also induce IL-27 expression ([@R83]; [@R5]; [@R42]). Together these results indicate that signaling pathways independent of type I and type II IFNs stimulate IL-27 expression leading to activation of STAT1-mediated diabetogenic activities.

Earlier studies have revealed that IL-27 signaling promotes the expression of T-bet and IFNγ production by CD4 T cells via STAT1-dependent signaling ([@R55]; [@R33]; [@R69]). Likewise, we observed that direct IL-27 signaling promoted the accumulation of T-bet^+^ CD4 T cells and enhanced their production of IFNγ in the spleen, PLN, and pancreatic islets. NOD mice deficient in T-bet are protected from T1D, and T-bet-deficient BDC2.5 CD4 T cells are impaired in their ability to transfer T1D ([@R14]). However, given the dispensable role of IFNγ signaling in T1D progression, IL-27-induced T-bet expression likely enhances the diabetogenic activity of CD4 T cells through an IFNγ-independent mechanism. Numerous studies have shown that CD4 T cells can provide help to CD8 T cells by directly activating DCs via IFNγ-dependent and IFNγ-independent mechanisms ([@R25]). Insulin reactive CD4 T cells and myeloid APCs are among the first cells to infiltrate the pancreatic islets ([@R74]; [@R17]). CD11b^−^ CD103^+^ migratory DCs are critical for autoreactive CD8 T cell activation in PLNs and DC maturation in islets precedes their migration to the PLN ([@R46]; [@R18]). Furthermore, transfer of autoreactive CD4 T cells induced maturation of migratory DCs in the pancreatic islets ([@R46]). Interestingly, we show here that in the absence of IL-27 signaling, there is limited DC and T cell infiltration in the islets and minimal expression of CD40 on myeloid APC subsets over time. Moreover, antigenic-specific activation of autoreactive CD8 T cells was suppressed in the PLN of IL-27-deficient hosts. Together, these results suggest that in the absence of IL-27 signaling, DC infiltration to the pancreatic islets and antigen trafficking to the PLN are insufficient to activate CD8 T cells and amplify the autoimmune response. Interestingly, we found that direct IL-27 signaling in myeloid APCs was not sufficient or required for T1D progression. This suggests that CD4 T cell-intrinsic IL-27 signaling promotes their ability to activate APCs in the pancreatic islets. Further experiments are required to determine whether this effect is T-bet dependent.

IL-27 can also signal through activation of STAT3 ([@R30]). The role of STAT3 in mediating T1D is difficult to discern because of the embryonic lethality of global STAT3-deficient mice ([@R68]). Multiple cytokines signaling through STAT3 activation have been implicated in human and NOD mouse T1D pathogenesis, including IL-2, IL-6, IL-15, and IL-21 ([@R70]; [@R26]; [@R31]; [@R27]; [@R8]; [@R82]; [@R65]; [@R66]; [@R16]). Although IL-6 has been implicated in human T1D, we did not observe a significant role of this cytokine in diabetes development in NOD mice. It has been previously demonstrated that IL-27 signaling can upregulate IL-21 expression in both human and mouse CD4 T cells via STAT3-dependent signaling ([@R3]). Significantly, NOD.*Il21*^−/−^ and NOD.*Il21r*^−/−^ mice are both completely protected from T1D ([@R66]; [@R65]; [@R9]). Specifically, CD4 T cell-derived IL-21 is required for T1D progression, and IL-21R-deficient CD4 and CD8 T cells are impaired in their ability to transfer T1D ([@R44]). Furthermore, IL-21 signaling promotes the migration and co-stimulatory functions of DCs during T1D progression ([@R75]). Therefore, it is conceivable that the reduced diabetogenicity of IL-27Rα-deficient CD4 T cells could be due to an inability to produce IL-21. The concept that IL-27-induced IL-21 production by CD4 T cells may drive autoimmune pathogenesis is further supported by two observations in the progression of Sjögren syndrome: (1) our observation that IL-27 signaling in T cells is required for lacrimal and salivary gland inflammation and (2) IL-21 expression in T cells correlates with the degree of lymphocytic infiltration in labial salivary glands in patients with Sjögren syndrome ([@R34]).

In addition to the indirect effect of IL-27 through CD4 T cells, IL-27 can also signal directly in CD8 T cells. Several *in vitro* studies have shown that IL-27 signals through STAT1 and STAT3 in CD8 T cells and promotes the expression of molecules important for an effector response, including T-bet, EOMES, IFNγ, and granzyme B ([@R60]; [@R48], [@R49]). Yet the direct effects of IL-27 on CD8 T cells *in vivo* remain understudied. [@R53] found that direct IL-27 signaling was critical for the generation of a robust antigen-specific CD8 T cell response to subunit vaccination. However, it is unclear whether the mechanisms governing the expansion of autoreactive CD8 T cells are parallel to those observed in infectious conditions. In the present study we found CD8 T cell-intrinsic IL-27 signaling to be important for T1D progression. Although direct IL-27 signaling did not have a marked effect on the effector phenotype of CD8 T cells in the spleen or PLN, it promoted the accumulation of CD8 T cells and enhanced their expression of T-bet and IFNγ in the pancreatic islets. These results are consistent with the previous observation that CD8 T cells undergo further differentiation within the local islet environment ([@R22], [@R23]). The role of IL-27 in CD8 T cells in T1D is further supported by a previous study in which islet inflammation and heightened CD8 T cell responses were observed in mice transgenically overexpressing IL-27 ([@R79]). Additional research is warranted to determine the effect of islet-centric CD8 T cell differentiation on T1D progression and the role of intrinsic IL-27 signaling in this process.

In the context of Sjögren syndrome, the role of IL-27 has not previously been well established. In Sjögren syndrome patients, serum levels of IL-27 were elevated ([@R80]); however, whether this reflected a pathogenic process driving inflammation versus a regulatory process driven by the inflammation was not known. In another mouse model of Sjögren syndrome, overexpression of IL-27 systemically by adeno-associated viral vector-mediated gene therapy resulted in decreases in IL-17 and IL-17-producing Th17 cells ([@R40]). This was associated with improvement in some disease parameters but had less of an effect on degree of inflammation within target organs. Regardless, that study suggested a possible immunoregulatory role for IL-27 when administered later in disease. In contrast, our findings demonstrate a requirement for IL-27 early in disease development, Because the lack of IL-27 or IL-27Rα in NOD mice prevented lacrimal and salivary gland inflammation, which is the earliest recognizable hallmark of Sjögren syndrome in mice or humans. This difference in the pathogenic versus protective role for IL-27 may reflect the complex immunostimulatory and immunomodulatory effects of IL-27 along with the complex roles of different lymphocyte populations in the development and progression of Sjögren syndrome-like disease in NOD mice. It is possible that IL-17 plays a pathogenic role in progression of disease, and thus, skewing away from IL-17 production through overexpression of IL-27 may limit later disease progression.

In conclusion, we identified IL-27 as an important mediator in the pathogenesis of T1D and Sjögren syndrome, and this was attributed to the effect of IL-27 signaling on the function of CD4 and CD8 T cells. Although several mechanistic questions remain, this study highlights the potential of IL-27 to be a viable therapeutic target for the treatment of autoimmune pathologies and advances our basic understanding of the function of a human T1D candidate gene.

STAR★METHODS {#S14}
============

Detailed methods are provided in the online version of this paper and include the following:

LEAD CONTACT AND MATERIALS AVAILABILITY {#S15}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Yi-Guang Chen (<yichen@mcw.edu>). All unique mouse strains generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S16}
--------------------------------------

NOD/ShiLtJ (NOD), NOD.Cg-Tg(TcraTcrbNY8.3)1Pesa/DvsJ (NOD.*NY8.3*), NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/DoiJ (NOD.*BDC2.5*), NOD.129S7(B6)-*Rag1*^*tm1Mom*^/J (NOD.*Rag1*^−/−^), and NOD.B6-*Ptprc*^*b*^/6908MrkTacJ (NOD.*Cd45.2*) mice were obtained from The Jackson Laboratory and subsequently maintained at the Medical College of Wisconsin (MCW) or University of Iowa (U Iowa). NOD.*Il27*^−/−^ mice were generated using ZFNs as previously described ([@R10]). Constructs of the ZFN pairs specifically targeting the fourth coding exon of the mouse *Il27* gene were designed, assembled, and validated by Sigma-Aldrich (target sequence CTACCACACTTCGGCCCTtccctGCCATGCTGGGAGGGCTG; ZFNs bind to each sequence shown in upper case on opposite strands). Forward (5′-AAACTTGTGAATGAAATGGAAGC-3′) and reverse (5′-TTCAACCTGATTCTGGGAG-3′) primers were used for PCR followed by Sanger sequencing. A founder heterozygous for a one bp deletion predicted to disrupt the normal reading frame and introduce a premature stop codon was identified and backcrossed to NOD. N2 heterozygous mutant mice were then intercrossed to fix the mutation to homozygosity. NOD.*Il27ra*^−/−^ mice were generated using the CRISPR/Cas9 technology as previously described ([@R58]). NOD embryos were intra-cytoplasmic microinjected with 3 pl of a solution containing Cas9 mRNA and single guide RNA (sgRNA) at respective concentrations of 100 μg/ml and 50 μg/ml. The guide RNA sequence (5′-TGCTACAGCGTCGGTCCCCTGGG-3′) was designed to target the second coding exon of *Il27ra*. The genomic region around the targeted site was amplified by PCR using forward (5′-AACTTGACCACGGTCCTCTC-3′) and reverse (5′-AATGAGTGGGCTAGCCT GAG-3′) primers and screened by Sanger sequencing. A founder heterozygous for a 34 bp deletion predicted to disrupt the normal reading frame was identified and backcrossed to NOD. At the N2 generation, heterozygous mutant mice were intercrossed to fix the mutation to homozygosity. The generation of NOD.*Rag1*^−/−^.*Il27*^−/−^ and NOD.*Rag1*^−/−^.*Il27ra*^−/−^ mice was accomplished by respectively outcrossing NOD.*Il27*^−/−^ and NOD.*Il27ra*^−/−^ mice to the NOD.*Rag1*^−/−^ strain. Similarly, the NOD.*Cd45.2.NY8.3* mice were generated by outcrossing NOD.*Cd45.2* to the NOD.NY8.3 strain. B6.129S2-Il6tm1Kopf/J mice ([@R39]) obtained from The Jackson Laboratory were initially backcrossed to NOD/ShiLtJ for 10 generations and then to NOD/LtDvs for three additional generations before intercrossing to generate littermates for the diabetes incidence study. All known insulin dependent diabetes susceptibility (*Idd*) regions were confirmed to be of NOD origin ([@R13]). All mice were used in accordance with Institutional Animal Care and Use Committee guidelines at the MCW and U Iowa. Mice used for experiments were housed in the same facility at either the MCW or U Iowa.

METHOD DETAILS {#S17}
--------------

### Assessment of T1D and insulitis {#S18}

Mice were tested weekly for glycosuria (Bayer Diastix ®) and considered diabetic with two consecutive readings \> 250 mg/dl. Pancreata from 10-week and 30-week-old non-diabetic mice were fixed in 10% neutral buffered formalin and 4μm sections were cut, discarding 60μm in between each section. The pancreatic sections were then stained with aldehyde fuchsin followed by a hematoxylin and eosin (H&E) counterstain. At least 30 islets were scored per mouse. Insulitis scores were determined as follows: 0-no infiltration, 1-leukocytes surrounding islet but no penetration, 2-estimated loss of up to 25% of the β cells, 3-estimated loss of up to 75% of the β cells, 4-end stage, less than 25% of the β cells remaining.

### Generation of bone marrow chimeras {#S19}

Bone marrow (BM) cells were harvested from the tibias and femurs of NOD.*Rag1*^−/−^ or NOD.*Il27*^−/−^. *Rag1*^−/−^ females (7--12 weeks old). BM cells (5 × 10^6^) were injected intravenously into sublethally irradiated (600 rads) NOD.*Il27*^−/−^ or NOD.*Il27ra*^−/−^ female mice (5--7 weeks old). For the generation of mixed BM chimeras, BM cells were collected from 6--9-week-old NOD.*Il27ra*^−/−^ and NOD.*Cd45.2* females. T cells were depleted using anti-CD3e microbeads (Miltenyi Biotec). T cell-depleted NOD.*Il27ra*^−/−^ and NOD.*Cd45.2* BM cells were mixed at a 1:1 ratio (2.5×10^6^ cells each) and infused into lethally irradiated (1100 rads) 6--8-week-old (NOD × NOD.*Cd45.2*)F1 females.

### Adoptive T cell transfer {#S20}

Splenic total T cells were isolated by negative selection (Pan T cell isolation kit II, Miltenyi Biotec) from NOD (6--13 weeks old), NOD.*Il27*^−/−^ (14--16 weeks old), or NOD.*Il27ra*^−/−^ females (12--15 weeks old) and intravenously injected (5×10^6^ cells) into NOD.*Rag1*^−/−^, NOD.*Rag1*^−/−^.*Il27*^−/−^ or NOD.*Rag1*^−/−^.*Il27ra*^−/−^ female recipients. In some experiments, splenic CD4 and CD8 T cells were independently isolated from 6--8-week-old NOD and NOD. *Il27ra*^−/−^ females, mixed at a 2:1 ratio (6×10^6^ cells total), and transferred into NOD.*Rag1*^−/−^ female recipients. The purity of the transferred T cells was analyzed by flow cytometry and was consistently \> 93%. To test the function of Tregs in vivo, splenic CD25 depleted total T cells were isolated from 13--15-week old female NOD mice by negative selection (Pan T cell isolation kit II, Miltenyi Biotec) with the addition of biotin conjugated anti-CD25 (7D4), (BD Biosciences). Splenic Tregs were independently isolated by fluorescence-activated cell sorting (FACS) from 6--9-week-old NOD or NOD.*Il27ra*^−/−^ mice. Flow cytometry verified that similar portions (\> 92%) of CD3^+^CD4^+^CD25^+^GITR^+^ splenocytes from both NOD and NOD.*Il27ra* ^−/−^ mice were also FOXP3^+^. Therefore, Tregs were sorted by gating on single, CD4^+^CD25^+^GITR^+^ cells using clones RM4--5, PC61 and DTA-1, respectively, and a BD FACSAria II cytometer. Splenic CD25 depleted NOD total T cells (5×10^6^) were co-transferred with or without splenic Tregs (5×10^5^) into NOD.*Rag1*^−/−^ recipients.

### *In vivo* cell proliferation assay {#S21}

Splenic CD8 T cells or CD4 T cells were isolated by negative selection (CD8^+^ T cell isolation kit or CD4^+^ T cell isolation kit, Miltenyi Biotec) from NOD.*NY8.3* or NOD.*BDC2.5* mice respectively. Isolated cells were labeled with 2.5μM eFluor670 (eBioscience) in Hanks balanced salt solution (HBSS, Sigma) at 37°C for 10 minutes and washed four times with complete RPMI. Labeled CD8 T cells were intravenously injected into sex-matched NOD and NOD.*Il27*^−/−^ males (3 × 10^6^) or females (5 × 10^6^). Labeled CD4 T cells were intravenously injected into NOD or NOD.*Il27*^−/−^ females (2 × 10^6^). Five days post-transfer, PLNs were harvested from recipients and analyzed by flow cytometry. In some experiments, splenic CD8 T cells were isolated by negative selection from NOD.*Cd45.2.NY8.3* females and intravenously injected into NOD or NOD.*Il27*^−/−^ females (5×10^6^). One day post-transfer, PLNs were harvested from recipients and analyzed by flow cytometry.

### Flow cytometry {#S22}

Fluorochrome-conjugated antibodies specific for CD45.1 (A20), CD45.2 (104), CD3ε (145--2C11 or 17A2) or TCRβ (H57--597), CD4 (RM4--5 or GK1.5), CD8α (53--6.7), IL-27Rα (2918), CD44 (IM7), CD62L (MEL-14), Foxp3 (FJK-16 s), CD25 (PC61), T-bet (eBIO4B10), IFNγ (XMG1.2), IL-17A (eBio17B7), IL-4 (11B11), CD11b (M1--70), CD11c (N418), I-A^g7^ (AMS32.1), H-2Kd (SF1--1.1.1), CD103 (2E7), F4/80 (BM8), CD49b (DX5), CD40 (3/(23)), CD80 (16--10A1), CD86 (GL1), PD-L1 (MIH5), and PDCA-1 (eBIO129c) were purchased from BD Biosciences (San Jose, CA), Bio-Legend (San Diego, CA), or Thermo Fisher Scientific (Waltham, MA). MHC class I (K^d^) tetramers loaded with a mimotope peptide NRP-V7([@R73]) were obtained from the National Institutes of Health Tetramer Core Facility. Single cell suspensions were prepared from the spleen, PLN, or thymus at the indicated age by passing the tissue through an 80μm Nitex screen (Dynamic Aqua Supply Ltd). For analysis of DC subsets, spleens and PLNs were digested for 30 minutes at 37°C in collagenase D (400 units/mL, Sigma) and agitated with a disposable transfer pipette to obtain a single cell suspension. Cells were washed with modified HBSS (Sigma), and then washed with FACS buffer (sodium azide (1mg/mL) and 2% fetal bovine serum (FBS, GIBCO) in phosphate buffered saline (D-PBS, GIBCO)) before staining. For analysis of islet-infiltrating cells, pancreatic islets were harvested by perfusion of the pancreas with a collagenase P solution (0.5 units/mL collagenase, Roche Diagnostics, 10mg/mL DNase, Sigma, diluted in HBSS) via the common bile duct using a 30-gauge needle. The inflated pancreata were incubated for 16 minutes at 37°C, agitated, and washed three times with HBSS plus 2% FBS. Islets were hand-picked from the pancreas suspension using a dissecting microscope and micropipette. Hand-picked islets were dissociated in non-enzymatic cell dissociation buffer (GIBCO) to obtain a single cell suspension. Cells were washed with FACS buffer before staining. For all experiments, cells were blocked with Fc block (anti-mouse CD16/CD32 clone 2.4G2, BioXCell) at room temperature for 10 minutes and then stained with the indicated antibodies for 30 minutes at 4°C. Stained cells were washed with FACS buffer. Dead cells were discriminated using 7-aminoactinomycin (7AAD, Sigma). For intracellular cytokine staining, cells were cultured at 37°C for four hours in the presence of phorbol myristate acetate (PMA, 20ng/mL, Sigma), ionomycin (1μg/mL, Sigma), and BD GolgiPlug™ (1μL/mL). Cultured cells were washed with FACS buffer before staining. For intracellular staining of cytokines and transcription factors, cells were fixed and permeabilized using the Foxp3/Transcription factor staining buffer set (eBioscience) according to the instructions. Dead cells were discriminated by fixable viability stain 575V (BD Biosciences) in the cultured samples from mixed BM chimera mice. Samples were run on the LSRII or LSRFortessa X20 cytometer (BD Biosciences). Data was analyzed with FlowJo software (Tree Star, Ashland, OR). Gating for IFNγ, IL-17A, IL-4, and T-bet were based on samples stained with isotype controls at the same concentration as the corresponding antibody.

### *In vitro* Treg suppression assay {#S23}

CD4^+^CD25^−^ T cells (effectors) were isolated by negative selection and CD4^+^CD25^+^ T cells (Tregs) were isolated by the CD4^+^CD25^+^ Regulatory T cell isolation kit (Miltenyi Biotec) from the spleens of 7--9-week-old male NOD and NOD.*Il27ra*^−/−^ mice. Purity of isolated cells was checked by flow cytometry and was routinely \> 87% for CD4^+^CD25^−^ T cells and \> 90% for CD4^+^CD25^+^ T cells. Isolated CD4^+^CD25^−^ T cells were labeled with 2μM CFSE (Invitrogen) in HBSS at 37°C for 10 minutes and washed four times with complete RPMI. Labeled CD4^+^CD25^−^ T cells from NOD donors (5×10^4^) were co-cultured with decreasing numbers of CD4^+^CD25^+^ T cells from NOD, or NOD.*Il27ra*^−/−^ (5×10^4^, 2.5×10^4^, 1.25×10^4^, and 6.25×10^3^) and 2×10^5^ total splenocytes from NOD.*Rag1*^−/−^ mice in the presence of 1μg/mL anti-CD3 (145--211, eBioscience). Control wells containing labeled CD4^+^CD25^−^ T cells plus NOD.*Rag1*^−/−^ total splenocytes with or without anti-CD3 were included. Cells were incubated at 37°C for three days. Cells were then washed with FACS buffer and stained with anti-CD4 and 7AAD. Flow cytometry was used to measure the proliferation of effector T cells by dilution of CFSE. The percent suppression was calculated by \[percentage of divided CD4^+^CD25^−^ T cells (without Tregs) - percentage of divided CD4^+^CD25^−^ (with Tregs)\] / \[percentage of divided CD4^+^CD25^−^ T cells (without Tregs)\] × 100.

### IL-27 ELISA {#S24}

BM was harvested from the tibias and femurs of 8--10-week-old male NOD and NOD.*Il27*^−/−^ mice and cultured in non-tissue culture treated plates in the presence of 25ng/mL rmM-CSF (R&D Systems) at 37°C for seven days. The supernatant was removed, and the adherent cells were washed with PBS and incubated with non-enzymatic cell dissociation buffer (GIBCO) at 37°C for 10 minutes. Adherent cells were then lifted from the plate using a cell scraper. Cells were then stimulated for 24 hours at 37°C with 100ng/mL lipopolysaccharide (LPS). ELISA was performed using a kit (Invitrogen) according to the manufacturer's instruction to measure IL-27 heterodimers in the cell-free supernatant.

#### Adoptive transfer of Sjögren syndrome {#S25}

Splenic T cells from the indicated strains were enriched by magnetic sorting using a negative selection T cell purification kit according to the manufacturer's protocol (Miltenyi Biotech Inc, Auburn, CA). Enriched T cells were then labeled with fluorophore-conjugated anti-CD8a (clone 53--6.7), anti-CD4 (clone GK1.5 or RM4--5), and anti-CD25 (clone PC61) monoclonal antibodies and subjected to FACS using an Aria II or an Aria Fusion (BD Biosciences, San Jose, CA). CD4^+^CD25^−^ and CD8a^+^ cells were purified and collected together as effector T cells. Sorted populations were \> 94% TCRα positive based on post-sort purity analyses with anti-TCRα antibody (clone H57--597) acquired on a BD LSR II (BD Biosciences). For transfers, 4×10^6^ effector T cells were transferred intravenously via retro-orbital injection to sex-matched NOD-*scid* recipient mice. Seven weeks later, lacrimal glands were fixed for H&E analyses to quantify inflammation.

#### Histology of lacrimal and salivary glands {#S26}

Exorbital lacrimal and submandibular salivary glands were fixed in buffered formalin, processed, embedded in paraffin, and sectioned. Five μm sections of paired glands were stained with H&E and inflammation was quantified by light microscopy using standard focus scoring ([@R1]). Briefly, slides were analyzed at 10x magnification by a blinded observer to determine the number of mononuclear cell foci in tissue sections of male lacrimal or female salivary glands, with a focus defined as a cluster of at least 50 mononuclear cells. Slides were scanned using PathScan Enabler IV (Meyer Instruments, Houston, TX) to obtain digital images, and tissue areas were measured using ImageJ software (US National Institutes of Health, Bethesda, MD, USA) ([@R61]). Focus scores were calculated as number of foci per 4 mm^2^ tissue area. Samples with foci that were so numerous that they coalesced were designated as diffuse and assigned focus scores greater than the highest calculable value for that set of comparisons. Representative images were captured on a Leitz DM-RB research microscope with a Leica DCF700T digital camera using the Leica Application Suite X software (Leica Microsystems, Wetzlar, Germany).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S27}
---------------------------------------

Statistical significance was determined by Mann-Whitney test or Wilcoxon matched-pairs signed rank test as appropriate. Log-rank test was used for analyzing T1D incidence. Multiple group comparisons of non-normally distributed data (focus scores) were performed by Kruskal-Wallace with Dunn's multiple comparisons post-test to compare each knockout group to wild-type. All statistical tests were performed using GraphPad Prism 7 (La Jolla, CA). p \< 0.05 was considered significant: \* p \< 0.05, \*\* p \< 0.01, and \*\*\* p \< 0.005. Statistical details of individual experiments can be found in the figures and legends.

DATA AND CODE AVAILABILITY {#S28}
--------------------------

This study did not generate or analyze datasets or codes.
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![NOD.*Il27*^*−/−*^ Mice Are Completely Resistant to T1D\
(A) T1D incidence of NOD and NOD.*Il27*^*−/−*^ mice. \*\*\*p \< 0.005 by log rank test.\
(B) Summary of insulitis in female NOD and NOD.*Il27*^−/−^ mice.\
(C) Summary of insulitis in male NOD and NOD.*Il27*^*−/−*^ mice. Pancreatic islets were scored for insulitis: 0 = no infiltration, 1 = peri-insulitis, 2 = ≤25% β cell loss, 3 = between 25% and 75% β cell loss, 4 = \>75% β cell loss. Each symbol represents one mouse. The horizontal bar depicts the mean. More than 30 islets were scored for each mouse. \*\*p \< 0.01 by Mann-Whitney test. NS, not significant.\
(D) T1D incidence study of sublethally irradiated NOD.*Il27*^−/−^ females infused with BM cells (5 × 10^6^) from sex-matched NOD.*Rag1*^−/−^ or NOD.*Rag1*^−/−^.*Il27*^−/−^ mice as indicated. \*\*p \< 0.01 by log rank test.\
(E and F) T1D incidence study of adoptively transferred T cell recipients.\
(E) Splenic T cells (5 × 10^6^) were isolated from 6-week-old NOD females and transferred into sex-matched NOD.*Rag1*^−/−^ or NOD.*Rag1*^−/−^.*Il27*^−/−^ recipients.\
(F) Splenic T cells (5 × 10^6^) were isolated from young (6- to 7-week-old) NOD, old (11- to 13-week-old) NOD, or old (14- to 15-week-old) NOD.*Il27*^−/−^ mice and transferred into sex-matched NOD.*Rag1*^−/−^ recipients. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.005 by log rank test. NS, not significant.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1545829-f0002){#F1}

![IL-27 Deficiency Suppresses Islet Infiltration of DCs and T Cells\
(A) The percentages of CD45^+^ cells among single viable cells in the islets of 4- or 10-week-old NOD and NOD.*Il27*^−/−^ females.\
(B) The percentages of CD3^+^ T cells among CD45^+^ cells in the islets of 4- or 10-week-old NOD and NOD.*Il27*^−/−^ females. Cells were gated on viable, single, and CD45^+^ cells.\
(C) The percentages of F4/80^+^ single-positive (SP), F4/80^+^ CD11c^+^, and CD11c^+^ SP among myeloid APCs in the islets of 4- or 10-week-old NOD and NOD.*Il27*^−/−^ females. Cells were first gated on viable, single, CD45^+^, and CD3^−^ cells, followed by excluding F4/80^−^ CD11c^−^ cells. For (A)--(C), representative flow cytometry profiles are shown in the left panels, and summarized results are presented in the right panels. Summarized data are representative of two independent experiments. Each symbol represents a mouse. The horizontal line indicates the mean. \*p \< 0.05 by Mann-Whitney test.\
(D) Representative flow cytometry plots on the left depict I-A^g7^ and CD40 expression among myeloid APC subsets in the islets of 10-week-old NOD or NOD.*Il27*^−/−^ females. Summarized data on the right show geometric mean fluorescence intensity of I-A^g7^ or CD40 among F4/80^+^ SP, F4/80^+^ CD11c^+^, or CD11c^+^ SP APC subsets in the islet of 10-week-old NOD or NOD.*Il27*^−/−^ females. Summarized data are representative of two independent experiments. Each symbol represents a mouse. The horizontal bar depicts the mean. \*p \< 0.05 by Mann-Whitney test.\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1545829-f0003){#F2}

![Activation of β-Cell-Specific T Cells in NOD Versus NOD.*Il27*^−/−^ Recipients\
(A and B) Purified splenic BDC2.5 CD4 T cells (2 × 10^6^) were labeled with eFluor670 proliferation dye and transferred into 8- to 9-week-old female NOD or NOD.*Il27*^−/−^ recipients. PLNs were harvested 5 days post-transfer, and proliferation (A) and CD44 and CD62L expression (B) of CD4^+^eFluor670^+^ cells was analyzed using flow cytometry.\
(C and D) Purified splenic NY8.3 CD8 T cells (3 × 10^6^ to 5 × 10^6^) were labeled with eFluor670 proliferation dye and transferred into sex-matched 7- to 9-week-old NOD or NOD.*Il27*^−/−^ recipients. PLNs were harvested 5 days post-transfer, and proliferation (C) and CD44 and CD62L expression (D) of CD8^+^eFluor670^+^ cells were analyzed using flow cytometry.\
(E and F) Purified splenic CD45.2^+^ NY8.3 CD8 T cells (5 × 10^6^) were transferred into 7- to 9-week-old female NOD or NOD.*Il27*^−/−^ recipients (expressing CD45.1). Sixteen hours after transfer, PLNs were harvested and analyzed for CD69 (E) and CD44 (F) expression on CD45.2^+^CD8^+^NRP-V7 tetramer^+^ cells using flow cytometry.\
Representative flow cytometry profiles are shown in the left panels, and summarized results are presented in the right panels. Summarized results are from two or three independent experiments. Each symbol represents a mouse. The horizontal bar depicts the mean. \*p \< 0.05 and \*\*p \< 0.01 by Mann-Whitney test. NS, not significant.](nihms-1545829-f0004){#F3}

![T Cell-Intrinsic IL-27 Signaling Is Essential for the Development of T1D\
(A) T1D incidence of NOD and NOD.*Il27ra*^−/−^ mice. \*\*\*p \< 0.005 by log rank test.\
(B) Summary of insulitis in female NOD and NOD.*Il27ra*^−/−^ mice.\
(C) Summary of insulitis in male NOD and NOD.*Il27ra*^−/−^ mice. Pancreatic islets were scored for insulitis as in [Figure 1](#F1){ref-type="fig"}. Each symbol represents one mouse. The horizontal bar depicts the mean. \*\*p \< 0.01 by Mann-Whitney test. NS, not significant.\
(D) T1D incidence study of sublethally irradiated NOD.*Il27*^−/−^ or NOD.*Il27ra*^−/−^ females infused with BM cells (5 × 10^6^) from sex-matched NOD.*Rag1*^−/−^ mice as indicated. \*\*p \< 0.01 by log rank test.\
(E--G) Incidence of T1D in recipients of adoptively transferred T cells.\
(E) Splenic T cells (5 × 10^6^) were isolated from 6-week-old NOD females and transferred into sex-matched NOD.*Rag1*^−/−^ or NOD.*Rag1*^−/−^.*Il27ra*^−/−^ recipients. T1D incidence was not significantly different between recipient groups.\
(F) Splenic T cells (5 × 10^6^) were isolated from 6- to 11-week-old NOD or 11- to 15-week-old NOD.*Il27ra*^−/−^ females and transferred into sex-matched NOD.*Rag1*^−/−^ recipients. \*\*\*p \< 0.005 by log rank test.\
(G) Splenic CD4 (4 × 10^6^) and CD8 (2 × 10^6^) T cells were isolated from indicated 6- to 8-week-old female strains and co-transferred into sex-matched NOD.*Rag1*^−/−^ recipients. \*\*p \< 0.01 and \*\*\*p \< 0.005 by log rank test.\
(H) *In vitro* suppression function of NOD and NOD.*Il27ra*^−/−^ Tregs. Splenic CD4^+^CD25^−^ T cells were isolated from NOD mice, labeled with CFSE, and cultured either alone or in the presence of unlabeled CD4^+^CD25^+^ Tregs at the indicated ratios. Cells were activated with soluble anti-CD3 in the presence of NOD.*Rag1*^−/−^ splenocytes for 3 days, and proliferation was analyzed using flow cytometry. Representative histograms of CFSE dilution from one experiment are shown in [Figure S4](#SD1){ref-type="supplementary-material"}. Summarized data from three independent experiments are shown. The percentage suppression was calculated as \[percentage of divided CD4^+^CD25^−^ T cells (without Tregs) -- percentage of divided CD4^+^CD25^−^ (with Tregs)\]/\[percentage of divided CD4^+^CD25^−^ T cells (without Tregs)\] 3 100. Error bars represent SEM. The suppression function of NOD and NOD.*Il27ra*^−/−^ Tregs was not significantly different.\
(I) Incidence of T1D in recipients of adoptively transferred T cells. Splenic CD25^−^ T cells (5 × 10^6^) isolated from 13- to 15-week-old NOD females and splenic CD4^+^GITR^+^CD25^+^ Tregs (5 × 10^5^) FACS sorted from 6- to 9-week-old NOD or NOD.*Il27ra*^−/−^ females were co-transferred into sex-matched NOD.*Rag1*^−/−^ recipients. \*\*\*p \< 0.005 by log rank test. NS, Not significant.\
See also [Figures S1](#SD1){ref-type="supplementary-material"}, [S3](#SD1){ref-type="supplementary-material"}, and [S4](#SD1){ref-type="supplementary-material"}.](nihms-1545829-f0005){#F4}

![IL-27 Signaling Intrinsically Modulates CD4 and CD8 T Cell Subsets\
Lethally irradiated (NOD 3 NOD.*Cd45.2*)F1 mice were infused with equal numbers of T cell-depleted BM cells from NOD.*Cd45.2* and NOD.*Il27ra*^−/−^ donors. Pre-diabetic recipients were analyzed for wild-type (CD45.2^+^) and IL-27Rα-deficient (CD45.1^+^) T cell subsets 10--12 weeks after BM reconstitution.\
(A) Frequencies of total CD4 and CD8 T cells in the spleens and islets of the mixed BM chimeras. Representative flow cytometry profiles are shown in the left panels, and summarized results are presented in the right panels. Summarized results are representative of at least two independent experiments.\
(B) T-bet expression in CD3^+^CD4^+^Foxp3^−^ T cells in the spleens, PLNs, and islets of mixed BM chimeras. Representative flow cytometry profiles are shown in the left panels, and summarized results are presented in the right panels.\
(C) IFNγ production in CD3^+^CD4^+^Foxp3^−^ T cells in the spleens, PLNs, and islets of mixed BM chimeras. Cells were stimulated with PMA and ionomycin. Representative flow cytometry profiles are shown in the left panels, and summarized results are presented in the right panels.\
(D) Frequencies of CD3^+^CD4^+^Foxp3^+^ Tregs in the spleens, PLNs, and islets of the mixed BM chimeras. Representative flow cytometry profiles are shown in the left panels, and summarized results are presented in the upper middle and right panels. The ratios of IL-27Rα-deficient to wild-type Treg frequencies in spleens versus islets are shown in the lower middle panel. The levels of CD25 expression are summarized in the lower right panel.\
(E) T-bet expression in CD3^+^CD8^+^ T cells in the spleens, PLNs, and islets of mixed BM chimeras. Representative flow cytometry profiles are shown in the left panels, and summarized results are presented in the right panels.\
(F) IFNγ production in CD3^+^CD8^+^ T cells in the spleens, PLNs, and islets of mixed BM chimeras. Cells were stimulated with PMA and ionomycin. Representative flow cytometry profiles are shown in the left panels, and summarized results are presented in the right panels.\
All summarized data in (B)--(F) are from two independent experiments. Statistical significance was determined using Wilcoxon matched-pairs signed rank test (\*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.005). NS, not significant. GMFI, geometric mean fluorescence intensity. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1545829-f0006){#F5}

![Effector T Cells Require IL-27 Signaling for Sjögren Syndrome-like Inflammation in NOD Mice\
(A and B) Quantification of inflammation of male lacrimal (A) and female salivary (B) glands from 10-week-old NOD, NOD.*Il27*^−/−^, and NOD.*Il27ra*^−/−^ mice. Symbols represent individual mice, and lines are medians. p \< 0.0001 (A) and p = 0.0014 (B) by Kruskal-Wallace test with Dunn's post-test p values as indicated. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.005.\
(C) Graph depicts quantification of inflammation of male lacrimal glands from 21-week-old NOD and NOD.*Il27ra*^−/−^ mice. Symbols represent individual mice, and lines are medians. Boxed symbol represents diffuse inflammation with foci so numerous that they coalesced, preventing accurate enumeration. \*p \< 0.05 by Mann-Whitney test. Histology images are H&E-stained tissue sections representative of NOD (top) and NOD.*Il27ra*^−/−^ (bottom) mice and demonstrate the characteristic focal inflammatory cell infiltrates that are more abundant in NOD lacrimal glands. Scale bar is 1 mm.\
(D) Quantification of lacrimal gland inflammation in male NOD-*scid* recipients of sorted effector T cells (CD8^+^ and CD4^+^CD25^−^ sorted together) from spleens of male NOD or NOD.*Il27ra*^−/−^ mice. Symbols represent individual mice pooled from two independent transfers. Lines are medians. \*\*\*p \< 0.005 by Mann-Whitney test.](nihms-1545829-f0007){#F6}

  REAGENT or RESOURCE                                                      SOURCE                                IDENTIFIER
  ------------------------------------------------------------------------ ------------------------------------- -------------------------------------------------------------------------------------
  Antibodies                                                                                                     
  Anti-mouse CD16/CD32                                                     BioXCell                              Clone 2.4G2, cat\#BE0307; RRID:AB_2736987
  Biotin anti-mouse CD25                                                   BD PharMingen                         Clone 7D4, cat\#553070; RRID:AB_394602
  anti-mouse CD4 (eFluor450 or PE-Cy7)                                     eBioscience                           Clone GK1.5, cat\#48--0041--82 or 25--0041--81; RRID:AB_10718983 or RRID:AB_469575
  APC-Cy7 anti-mouse CD4                                                   BD PharMingen                         Clone GK1.5, cat\#552051; RRID:AB_394331
  AF700 anti-mouse CD4                                                     eBioscience                           Clone RM4--5, cat\#56--0042--82; RRID:AB_494000
  eFluor450 anti-mouse CD25                                                eBioscience                           Clone PC61.5, cat\#48--0251--82; RRID:AB_10671550
  PE anti-mouse GITR                                                       eBioscience                           Clone DTA-1, cat\#12--5874--80; RRID:AB_465985
  APC-Cy7 anti-mouse CD45.1                                                BioLegend                             Clone A20, cat\#110716; RRID:AB_313505
  eFluor450 anti-mouse CD45.1                                              Invitrogen                            Clone A20, cat\#48--0453--82; RRID:AB_1272189
  AF700 anti-mouse CD45.2                                                  BioLegend                             Clone 104, cat\#109822; RRID:AB_493731
  PE-Cy7 anti-mouse CD45.2                                                 BD Biociences                         Slone 104, cat\#560696; AB_1727494
  Brilliant Violent 510 anti-mouse CD3ε                                    BioLegend                             Clone 17A2, cat\#100234; RRID:AB_2562555
  PE-Cy5 anti-mouse CD3ε                                                   BioLegend                             Clone 145--2C11, cat\#100310; RRID:AB_312675
  BUV395 anti-mouse CD3ε                                                   BD Bioscience                         Clone 145--2C11, cat\#563565; RRID:AB_2738278
  FITC anti-mouse CD3ε                                                     eBioscience                           Clone 145--2C11, cat\#11--0031--85; RRID:AB_464883
  APC anti-mouse TCRβ                                                      BD PharMingen                         Clone H57--597, cat\#553174; RRID:AB_398534
  anti-mouse CD8α (BUV395 or PE)                                           BD Biosciences                        Clone 53--6.7, cat\#563786 or 553032; RRID:AB_2732919 or RRID:AB_394570
  PE-Cy7 anti-mouse CD8α                                                   Invitrogen                            Clone 53--6.7, cat\#25--0081--82; RRID:AB_469584
  PE anti-mouse IL-27Rα                                                    BD PharMingen                         Clone 2918, cat\#564337; RRID:AB_2738753
  FITC anti-mouse CD44                                                     eBioscience                           Clone IM7, cat\#11--0441--85; RRID:AB_465046
  PE anti-mouse CD62L                                                      eBioscience                           Clone MEL-14, cat\#12--0621--81; RRID:AB_465720
  APC anti-mouse Foxp3                                                     Invitrogen                            Clone FJK-16 s, cat\#17--5773--82; RRID:AB_469457
  PE-Cy5 anti-mouse Foxp3                                                  eBioscience                           Clone FJK-16 s, cat\#15--5773--82; RRID:AB_468806
  PE anti-mouse T-bet                                                      eBioscience                           Clone eBio4B10, cat\#12--5825--82; RRID:AB_925761
  APC anti-mouse IFN-γ                                                     BD Biosciences                        Clone XMG1.2, cat\#554413; RRID:AB_398551
  PE-Cy7 anti-mouse IL-17                                                  eBioscience                           Clone eBIO17B7, cat\# 25--7177--80; RRID:AB_10717952
  PE anti-mouse IL-4                                                       BD Biosciences                        Clone 11B11, cat\#562044; RRID:AB_10896652
  APC anti-mouse H2-K^d^                                                   eBioscience                           Clone SF1--1.1.1, cat\#17--5957--80; RRID:AB_1311278
  PE anti-mouse I-A^d^                                                     BD Biosciences                        Clone AMS32.1, cat\#553548; RRID:AB_394915
  APC anti-mouse CD103                                                     eBiscience                            Clone 2E7, cat\#17--1031--82; RRID:AB_1106992
  eFluor450 anti-mouse F4/80                                               Invitrogen                            Clone BM8, cat\#48--4801--82; RRID:AB_1548747
  Pacific Blue anti-mouse CD49b                                            Biolegend                             Clone DX5, cat\#108918; RRID:AB_2265144
  PE-Cy7 anti-mouse CD40                                                   Biolegend                             Clone 3/23, cat\#124621; RRID:AB_10933422
  PE anti-mouse CD40                                                       BD Biosciences                        Clone 3/23, cat\#553791; RRID:AB_395055
  FITC anti-mouse CD80                                                     Invitrogen                            Clone 16--10A1, cat\#11--0801--82; RRID:AB_465133
  Pacific Blue anti-mouse CD86                                             Biolegend                             Clone GL-1, cat\#105021; RRID:AB_493467
  PE anti-mouse PD-L1                                                      BD Biosciences                        Clone M1H5, cat\#558091; RRID:AB_397018
  PE anti-mouse PDCA-1                                                     eBioscience                           Clone eBIO129c, cat\#12--3171--82; RRID:AB_763424
  anti-mouse CD11c (APC or AF700)                                          eBioscience                           Clone N418, cat\#17--0114--81 or 56--0114--80; RRID:AB_469345 or RRID:AB_493993
  FITC anti-mouse CD11b                                                    BD Biosciences                        Clone M1/70, cat\#557396; RRID:AB_396679
  Purified NA/LE anti-mouse CD3e                                           BD PharMingen                         Clone 145--2C11, cat\#553057; RRID:AB_394590
  Chemicals, Peptides, and Recombinant Proteins                                                                  
  MHC Class I (Kd) tetramers loaded with NRP-V7                            NIH Tetramer Core Facility ([@R73])   N/A
  eFluor670                                                                eBioscience                           Cat\#65--0840--85
  7-aminoactinomycin D                                                     Sigma                                 Cat\#A9400--1MG
  Foxp3/Transcription Factor staining buffer set                           Invitrogen                            Cat\#00--5523--00
  Fixable Viability Stain 575V                                             BD Bioscience                         Cat\#565694
  Carboxyfluorescein succinimidyl ester                                    Invitrogen                            Cat\#V12883
  rmM-CSF                                                                  R&D Systems                           Cat\#416-ML
  Critical Commercial Assays                                                                                     
  Anti-CD3ε microbeads                                                     Miltenyi Biotec                       Cat\#130--094--973
  Pan T cell isolation kit II                                              Miltenyi Biotec                       Cat\#130--095--130
  CD8+ T cell isolation kit                                                Miltenyi Biotec                       Cat\#130--104--075
  CD4+ T cell isolation kit                                                Miltenyi Biotec                       Cat\#130--104--454
  CD4+CD25+ Regulatory T cell isolation kit                                Miltenyi Biotec                       Cat\#130--091--041
  IL-27 ELISA                                                              Invitrogen                            Cat\#88--7274--88
  Experimental Models: Organisms/Strains                                                                         
  NOD/ShiLtJ                                                               The Jackson Laboratory                JAX: 001976; RRID:IMSR_JAX:001976
  NOD.Cg-Tg(TcraTcrbNY8.3)1Pesa/DvsJ                                       The Jackson Laboratory                JAX: 005868; RRID:IMSR_JAX:005868
  NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/DoiJ                                The Jackson Laboratory                JAX: 004460; RRID:IMSR_JAX:004460
  NOD.129S7(B6)-*Rag1^tm1Mom^*/J                                           The Jackson Laboratory                JAX: 003729; RRID: IMSR_JAX:003729
  NOD.B6-*Ptprc^b^*/6908MrkTacJ                                            The Jackson Laboratory                JAX: 014149; RRID:IMSR_JAX:014149
  NOD.*Il27^−/−^*                                                          This Manuscript                       N/A
  NOD.*Il27ra^−/−^*                                                        This Manuscript                       N/A
  NOD.*Rag1^−/−^.Il27^−/−^*                                                This Manuscript                       N/A
  NOD.*Rag1^−/−^.Il27ra^−/−^*                                              This Manuscript                       N/A
  NOD.*Cd45.2.NY8.3*                                                       This Manuscript                       N/A
  NOD.*Il6^−/−^*                                                           This Manuscript                       N/A
  Oligonucleotides                                                                                               
  *Il27ra* sgRNA: TGCTACAGCGTCGGTCCCCTGGG                                  IDT                                   N/A
  Forward primer for NOD.*Il27^−/−^* genotyping: AAACTTGTGAATGAAATGGAAGC   IDT                                   N/A
  Reverse primer for NOD.*Il27^−/−^* genotyping: TTCAACCTGATTCTGGGAG       IDT                                   N/A
  Forward primer for NOD.*Il27ra^−/−^* genotyping: AACTTGACCACGGTCCTCTC    IDT                                   N/A
  Reverse primer for NOD.*Il27ra^−/−^* genotyping: AATGAGTGGGCTAGCCTGAG    IDT                                   N/A
  Software and Algorithms                                                                                        
  FlowJo 7.6.5                                                             FlowJo                                <https://www.flowjo.com>
  ImageJ                                                                   [@R61]                                <https://imagej.nih.gov/ij/>
  Application Suite X                                                      Lecia Microsystems                    <https://www.leica-microsystems.com/products/microscope-software/p/leica-las-x-id/>
  Prism 7                                                                  Graphpad                              <https://www.graphpad.com/scientific-software/prism/>

###### Highlights

-   NOD mice deficient in IL-27 or IL-27Rα are completely resistant to type 1 diabetes

-   T cell-intrinsic IL-27 signaling is essential for type 1 diabetes development

-   IL-27 directly alters the balance of Treg and effector T cells to favor the latter

-   T cells require IL-27 signaling for Sjögren syndrome-like inflammation in NOD mice
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